European Heart Journal· 2012Q1
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- 2,894citations
- Q1SCImago
- 2012year
Short summary
The 2012 ESC focused update on atrial fibrillation management emphasizes novel oral anticoagulants (NOACs) and left atrial appendage occlusion (LAAO) as key advancements, alongside refined strategies for rate/rhythm control and upstream therapy.
AI-generated from the title and abstract; the full text is not read.
Key points
- Novel oral anticoagulants (NOACs) and left atrial appendage occlusion (LAAO) are presented as important new therapeutic options.
- Updated guidance is provided on rate control, rhythm control, and cardioversion strategies.
- Recommendations for antiarrhythmic drug therapy and upstream therapy are refined.
- The update incorporates findings from major trials like RE-LY, impacting stroke risk stratification and management.
AI-generated from the title and abstract; the full text is not read.
Abstract
Atrial fibrillation; European Society of Cardiology; Guidelines; Anticoagulation; Novel oral anticoagulants; Left atrial appendage occlusion; Rate control; Cardioversion; Rhythm control; Antiarrhythmic drugs; Upstream therapy; Pulmonary vein isolation; Left atrial ablation; Focused update; RANDOMIZED CONTROLLED-TRIAL; HEART RHYTHM ASSOCIATION; NET CLINICAL BENEFIT; RE-LY TRIAL; STROKE RISK STRATIFICATION; ACUTE CORONARY SYNDROME; RADIOFREQUENCY CATHETER ABLATION; ANTIARRHYTHMIC-DRUG THERAPY; ORAL ANTICOAGULANT DRUGS; NORMALIZED RATIO CONTROL
The authors' abstract, as published at the source. European Heart Journal, 2012 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Cardiology and Cardiovascular Medicine
Cardiology and Cardiovascular MedicineMedicine